AU2020260154B2 - Triple helix terminator for efficient RNA trans-splicing - Google Patents

Triple helix terminator for efficient RNA trans-splicing

Info

Publication number
AU2020260154B2
AU2020260154B2 AU2020260154A AU2020260154A AU2020260154B2 AU 2020260154 B2 AU2020260154 B2 AU 2020260154B2 AU 2020260154 A AU2020260154 A AU 2020260154A AU 2020260154 A AU2020260154 A AU 2020260154A AU 2020260154 B2 AU2020260154 B2 AU 2020260154B2
Authority
AU
Australia
Prior art keywords
sequence
trans
splicing
gene
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020260154A
Other languages
English (en)
Other versions
AU2020260154A1 (en
Inventor
Jean Bennett
Krishna J. Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
Original Assignee
University of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania filed Critical University of Pennsylvania
Publication of AU2020260154A1 publication Critical patent/AU2020260154A1/en
Application granted granted Critical
Publication of AU2020260154B2 publication Critical patent/AU2020260154B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020260154A 2019-04-17 2020-04-17 Triple helix terminator for efficient RNA trans-splicing Active AU2020260154B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962835164P 2019-04-17 2019-04-17
US62/835,164 2019-04-17
PCT/US2020/028797 WO2020214973A1 (en) 2019-04-17 2020-04-17 Triple helix terminator for efficient rna trans-splicing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026220282 Division 2020-04-17

Publications (2)

Publication Number Publication Date
AU2020260154A1 AU2020260154A1 (en) 2021-11-11
AU2020260154B2 true AU2020260154B2 (en) 2026-05-21

Family

ID=72837942

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020260154A Active AU2020260154B2 (en) 2019-04-17 2020-04-17 Triple helix terminator for efficient RNA trans-splicing

Country Status (11)

Country Link
US (1) US20220204989A1 (cg-RX-API-DMAC7.html)
EP (1) EP3956442A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022529065A (cg-RX-API-DMAC7.html)
KR (1) KR20220002910A (cg-RX-API-DMAC7.html)
CN (1) CN114040974B (cg-RX-API-DMAC7.html)
AU (1) AU2020260154B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020539A2 (cg-RX-API-DMAC7.html)
CA (1) CA3133555A1 (cg-RX-API-DMAC7.html)
IL (1) IL287243A (cg-RX-API-DMAC7.html)
MX (1) MX2021012702A (cg-RX-API-DMAC7.html)
WO (1) WO2020214973A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250150157A (ko) 2018-04-17 2025-10-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 트랜스-스플라이싱 분자
BR112021020539A2 (pt) * 2019-04-17 2022-01-04 Univ Pennsylvania Terminador de hélice tripla para trans-splicing de rna eficiente
EP4323391A4 (en) * 2021-04-15 2025-04-16 Tacit Therapeutics, Inc. HIGH-EFFICIENCY TRANS-SPLICING FOR TARGETED RNA SEQUENCE REPLACEMENT IN HUMAN CELLS
JP2024533163A (ja) 2021-09-03 2024-09-12 タシト・セラピューティクス・インコーポレーテッド スプライソソーム構成要素のリクルートを介したrna編集
WO2023205694A2 (en) * 2022-04-20 2023-10-26 Tacit Therapeutics, Inc. Stabilization of therapeutic trans-splicing rna molecules in human cells
EP4519436A4 (en) * 2022-05-03 2026-08-19 Tacit Therapeutics Inc LOCALIZATION OF NUCLEIC ACID MOLECULES TRANS-SPLICING TO AND WITHIN THE CELL NUCLEUS
KR20250011939A (ko) * 2022-05-13 2025-01-22 아시디엔 테라퓨틱스, 인크. Abca4 트랜스-스플라이싱 분자
EP4622662A1 (en) 2022-11-23 2025-10-01 Amber Bio Inc. Gene-modifying endonucleases
US12686869B1 (en) 2026-01-23 2026-07-21 Amber Bio Inc. Methods and compositions for trans-splicing utilizing trifunctional elements

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180369412A1 (en) * 2015-11-19 2018-12-27 The Trustees Of The University Of Pennsylvania Compositions and Methods for Correction of Heritable Ocular Disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2151248A1 (en) * 2008-07-30 2010-02-10 Johann Bauer Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses
CN104955951A (zh) * 2012-10-16 2015-09-30 麻省理工学院 稳定的非多腺苷酸化rna的产生
GB201219762D0 (en) * 2012-11-02 2012-12-19 Bauer Johann A RNA trans-splicing molecule (RTM) for use in the treatment of cancer
DK2986635T3 (en) * 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
US11795455B2 (en) * 2017-07-31 2023-10-24 Massachusetts Institute Of Technology RNA cleavage-induced transcript stabilizer and uses thereof
KR20250150157A (ko) * 2018-04-17 2025-10-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 트랜스-스플라이싱 분자
BR112021020539A2 (pt) * 2019-04-17 2022-01-04 Univ Pennsylvania Terminador de hélice tripla para trans-splicing de rna eficiente

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180369412A1 (en) * 2015-11-19 2018-12-27 The Trustees Of The University Of Pennsylvania Compositions and Methods for Correction of Heritable Ocular Disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCOTT J. DOOLEY, DEVIN S. MCDOUGALD, KRISHNA J. FISHER, JEANETTE L. BENNICELLI, LLOYD G. MITCHELL, JEAN BENNETT: "Spliceosome-Mediated Pre-mRNA trans-Splicing Can Repair CEP290 mRNA", MOLECULAR THERAPY-NUCLEIC ACIDS, CELL PRESS, US, vol. 12, 1 September 2018 (2018-09-01), US, pages 294 - 308, XP055663498, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2018.05.014 *

Also Published As

Publication number Publication date
CA3133555A1 (en) 2020-10-22
CN114040974A (zh) 2022-02-11
WO2020214973A1 (en) 2020-10-22
MX2021012702A (es) 2022-01-24
EP3956442A1 (en) 2022-02-23
EP3956442A4 (en) 2023-01-25
US20220204989A1 (en) 2022-06-30
CN114040974B (zh) 2025-11-04
KR20220002910A (ko) 2022-01-07
JP2022529065A (ja) 2022-06-16
AU2020260154A1 (en) 2021-11-11
JP2025121988A (ja) 2025-08-20
IL287243A (en) 2021-12-01
BR112021020539A2 (pt) 2022-01-04

Similar Documents

Publication Publication Date Title
CN114040974B (zh) 用于高效rna反式剪接的三螺旋终止子
US12442003B2 (en) Trans-splicing molecules
AU2016355343A1 (en) Compositions and methods for correction of heritable ocular disease
JP2022174192A (ja) 多重ベクターシステム及びその使用
CN114829598A (zh) 一种治疗Usher综合征的方法和其组合物
ES2952598T3 (es) Edición génica de mutaciones intrónicas profundas
US20230038993A1 (en) Compositions and methods for treating cep290-associated disease
US20260001917A1 (en) Modified adeno-associated virus capsid proteins and methods thereof
KR20240004536A (ko) 달팽이관의 형질도입을 위한 아데노 관련 바이러스 벡터
US20200248204A1 (en) Methods of treating genetic hearing loss
CN114521214A (zh) 视紫红质转录体特异性反式剪接核酶及其用途
CN121464217A (zh) 用于治疗KIF1A相关神经紊乱的靶向KIF1A错义突变的RNAi
JP2024521713A (ja) Kcnv2変異体及びその使用
WO2026025441A1 (zh) 一种用于显性遗传的视网膜色素变性基因编辑药物载体
WO2025106562A1 (en) Mecp2 trans-splicing molecules
WO2026032020A1 (zh) Aav介导的rpgr x连锁视网膜变性的基因编辑治疗方法
AU2023330511A1 (en) Product preparation based on application of sgrna for the treatment of huntington's disease